Faculty

Katharine J Bar, MD

Associate Professor of Medicine (Infectious Diseases)

Department: Medicine

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

502 D Johnson Pavilion
3610 Hamilton Walk
Philadelphia, PA 19104-6073

Office: (215) 573-8497
Fax: (215) 349-5111

Email:
bark@pennmedicine.upenn.edu

Education:
BA (Biochemistry and African History, Honors)
Northwestern University, Evanston, IL, 1997.
MD
University of Iowa College of Medicine, Iowa City, IA, 2002.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

HIV care, general infectious disease care

Description of Research Expertise

The Bar Lab studies novel approaches to HIV prevention and cure. Our current research focuses on:
(i) characterizing the viral dynamics and host immune responses during virus suppression and treatment interruption,
(ii) developing NHP models that faithfully recapitulate HIV-1 latency and rebound, and
(iii) developing antibody-based interventions.

Selected Publications

Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest 134(9): e181576, May 2024.

Whitehill GD, Joy J, Marino FE, Krause R, Mallick S, Courtney H, Park K, Carey J, Hoh R, Hartig H, Pae V, Sarvadhavabhatla S, Donaire S, Deeks SG, Lynch RM, Lee SA, Bar KJ: Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1. J Clin Invest 134(11), April 2024.

Miner MD, deCamp A, Grunenberg N, De Rosa SC, Fiore-Gartland A, Bar K, Spearman P, Allen M, Yu PC, Manso B, Frahm N, Kalams S, Baden L, Keefer MC, Scott HM, Novak R, Van Tieu H, Tomaras GD, Kublin JG, McElrath MJ, Corey L, Frank I; HVTN 085 Study Team: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. EBioMedicine 100: 104987, Feb 2024.

Maurine D. Miner, Allan deCamp, Nicole Grunenberg, Stephen C. De Rosa, Andrew Fiore-Gartland, Katherine Bar, Paul Spearman, Mary Allen, Pei-Chun Yu, Bryce Manso, Nicole Frahm, Spyros Kalams, Lindsey Baden, Michael C. Keefer, Hyman M. Scott, Richard Novak, Hong Van Tieu, Georgia D. Tomaras, James G. Kublin, M. Juliana McElrath, Lawrence Corey, Ian Frank, Artur Kalichman, Paul Edlefsen, Mary Enama, John Hural, Renee Holt, Debora Dunbar, Dave Crawford, Ian Maki, Jan Johannessen, Scharla Estep, Yevgeny Grigoriev, Tamra Madenwald, Marianne Hansen, Drienna Holman, Ramey Fair, Genevieve Meyer, Anya Luke-Kilolam: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. eBioMedicine 100, Jan 2024.

Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S.: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun 14(1): 8299, Dec 2023.

Docken SS, McCormick K, Pampena MB, Samer S, Lindemuth E, Pinkevych M, Viox EG, Wu Y, Schlub TE, Cromer D, Keele BF, Paiardini M, Betts MR, Bar KJ, Davenport MP.: Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency. PLoS Pathog 19(11): e1011755, Nov 2023.

Tieu HV, Karuna S, Huang Y, Sobieszczyk ME, Zheng H, Tomaras GD, Montefiori DC, Shen M, DeRosa S, Cohen K, Isaacs MB, Regenold S, Heptinstall J, Seaton KE, Sawant S, Furch B, Pensiero M, Corey L, Bar KJ; HVTN 122 Study Team: Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine 41(42): 6309-6317, Oct 2023.

Podgorski RM, Robinson JA, Smith MD, Mallick S, Zhao H, Veazey RS, Kolson DL, Bar KJ, Burdo TH: Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques. Retrovirology 20(1): 13, Aug 2023.

Bauer A, Lindemuth E, Marino FE, Krause R, Joy J, Docken SS, Mallick S, McCormick K, Holt C, Georgiev I, Felber B, Keele BF, Veazey R, Davenport MP, Li H, Shaw GM, Bar KJ.: Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques. PLoS Pathog 19(7): e1011059, Jul 2023.

Tang Y, Chaillon A, Gianella S, Wong LM, Li D, Simermeyer TL, Porrachia M, Ignacio C, Woodworth B, Zhong D, Du J, de la Parra Polina E, Kirchherr J, Allard B, Clohosey ML, Moeser M, Sondgeroth AL, Whitehill GD, Singh V, Dashti A, Smith DM, Eron JJ, Bar KJ, Chahroudi A, Joseph SB, Archin NM, Margolis DM, Jiang G.: Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest 133(12), Jun 2023.